Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia

References

• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20
   PubMed Web of Science ®Google Scholar
• Glaspy J, Henry D, Patel R, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140-9
   PubMed Web of Science ®Google Scholar
• Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Williston Park) 2002;16:23-9
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1:131-8
   PubMedGoogle Scholar
• Canon J-L, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84
   PubMed Web of Science ®Google Scholar
• Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Aranesp (Darbepoetin alfa) Package Insert. Thousand Oaks, California, April 2009
   Google Scholar
• Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-49
   PubMed Web of Science ®Google Scholar
• Rodgers GM, Becker PS, Bennett CL, et al. NCCN Practice Guidelines in Oncology: Cancer and chemotherapy-induced anemia. National Comprehensive Cancer Network, 2008
   Google Scholar
• Boccia R, Malik IA, Raja V, et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 2006;11:409-17
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute, United States Department of Health and Human Services, 2003
   Google Scholar
• Rodgers GM, ed. Guidelines for supportive care: Cancer and treatment-related anemia. v.2.2004 edn: National Comprehensive Cancer Network. Available at: http://www.nccn.org/physician_gls/index.html. Accessed: March 24, 2005
   Google Scholar
• Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303-20
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16
   PubMed Web of Science ®Google Scholar
• Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34:13-19
   PubMed Web of Science ®Google Scholar
• Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-61
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82
   PubMed Web of Science ®Google Scholar
• Acs G, Xu X, Chu C, et al. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 2004;100:2376-86
   PubMed Web of Science ®Google Scholar
• Arcasoy MO, Amin K, Chou SC, et al. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 2005;11:20-7
   PubMed Web of Science ®Google Scholar
• Arcasoy MO, Amin K, Vollmer RT, et al. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 2005;18:421-30
   PubMed Web of Science ®Google Scholar
• Dagnon K, Pacary E, Commo F, et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res 2005;11:993-9
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Amgen Announces Interim Results of Aranesp “PREPARE” Study in Breast Cancer Patients. 2007 [cited 2007 November 30]; Available from: http://www.immunex.com/media/media_pr_detail.jsp?year=2007&releaseID=1083091
   Google Scholar
• Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. [see comment]. Lancet 2003;362:1255-60
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. [see comment]. J Clin Oncol 2005;23:5960-72
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hoff C, Sand Hansen H, et al. Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) – the Danish Head and Neck Cancer Group (DAHANCA 10). Eur J Cancer 2007;5:7 (Abstract)
   Web of Science ®Google Scholar
• Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. [see comment]. J Clin Oncol 2008;26:1040-50
   PubMed Web of Science ®Google Scholar
• Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108:317-25
   PubMed Web of Science ®Google Scholar
• Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.[see comment]. J Clin Oncol 2007;25:1027-32
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services US FDA. Summary Minutes of the Oncologic Drugs Advisory Committee. 2008 March 13, 2008 [cited May 5, 2008]; Available from: http://www.fda.gov/ohrms/dockets/ac/08/minutes/2008-4345m2.doc
   Google Scholar
• Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14
   PubMed Web of Science ®Google Scholar